Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Proof of principle to progress treatments

Jonathan Keats • 13 Sep 2019
IMW 2019
Multiple Myeloma

Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, suggests the progression of multiple myeloma treatment through the proof of principle approach at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Jonathan Keats

Moving away from FISH and towards NGS for genetic testing in multiple myeloma 1:09
Moving away from FISH and towards NGS for genetic testing in multiple myeloma
Jonathan Keats • 8 Dec 2024
An insight into the MMRF-CoMMpass study 2:49
An insight into the MMRF-CoMMpass study
Jonathan Keats • 26 Mar 2022
Sample processing and enrichment techniques in myeloma research 3:58
Sample processing and enrichment techniques in myeloma research
Jonathan Keats • 2 Sep 2021
A molecular-based approach to MM treatment 1:51
A molecular-based approach to MM treatment
Jonathan Keats • 15 Sep 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals